BCIQ Profiles

Company Profile Report
0429 ECP Capsida
BioCentury & Getty Images

Emerging Company Profile

With $50M A round led by Versant, Westlake, newco Capsida aims to target AAV vectors to specific tissues

Emerging Company Profile: Thousand Oaks, Calif.-based biotech is engineering AAV vectors to target specific tissues while avoiding the liver

With a $50 million series A led by Versant and Westlake, Thousand Oaks, Calif.-based Capsida is engineering AAV vectors to target specific tissues while avoiding the liver.

Apr 29, 2021 | 11:52 PM GMT

Capsida emerged from stealth on Thursday to tackle one of the biggest challenges holding AAV gene therapy back from becoming a mainstream modality — selective tissue targeting outside the liver.

Thousand

Read the full 1067 word article

How to gain access

Continue reading with a
two-week free trial.